Kornimate/medical-research-clean huggingface dataset:
effectiveness of an epilepsy application for self-management in viet nam

Conditions: Epilepsy

Summary: epilepsy is a common neurological disease which effects all genders, ages and geographic regions. self-management refers to "the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences of health conditions". optimal self-management may improve self-efficacy, knowledge about epilepsy of people with epilepsy (pwe) and family, medical compliance and avoidance of seizure triggers. this study aims to determine the effectiveness of the epilepsy app for pwe to improve self-management

epilepsy which affects over 70 million people worldwide, is one of the most common neurological diseases. epilepsy is "a disease characterized by an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological, and social consequences of this condition." therefore, self-management plays a crucial role for people with epilepsy (pwe) to adapt their lifestyles and behaviors for those long-lasting changes. self-management is a dynamic, interactive, and daily process in which individuals engage to manage a chronic illness. self-management is "the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences of health conditions." optimal self-management may improve self-efficacy, knowledge about epilepsy of pwe and family, medical compliance, and avoidance of seizure triggers. mobile health (mhealth) epilepsy application (apps) refers to any digital software (e.g., via the internet, mobile device, wearable, or desktop platforms) capable of collecting, tracking, or sharing data while interacting with patients about their epilepsy health information. recent studies have reported that mhealth applications improved the management of people with chronic illnesses, including epilepsy. in the digital era, smartphones are becoming more and more popular worldwide. in 2016, there were 24.8 million (30% of the population) smartphone users in viet nam, and this share is predicted to rise by 40 percent by 2021. nanacara is an educational app for pwe to improve self-management. a systematic review showed 20 english apps designed to improve self-management for pwe. only one randomized clinical trial (rct) study showed the effectiveness of mobile apps in increasing self-management for pwe. this result implied the lack of validation study related to the clinical use of the epilepsy apps. this study aims to determine the effectiveness of the epilepsy app for pwe to improve self-management.

Eligibility criteria:
inclusion criteria: * people with epilepsy diagnosed and treated by neurologists * smartphone users exclusion criteria: * substance dependence * suicidality * limited language proficiency

Keywords: epilepsy self-management mobile health application effectiveness
third year evaluation on genistein efficacy and safety

Conditions: Menopause; Osteopenia

Summary: background: recent evidences showed that the phytoestrogen genistein positively affects bone metabolism with no clinically significant adverse effects in a cohort of osteopenic, postmenopausal women. however, there is still a knowledge gap regarding the long-term safety of genistein on the breast, the uterus, the thyroid gland and its efficacy in postmenopausal women. objective: to assess the safety profile of genistein on mammary and thyroid glands and endometrium and cardiovascular apparatus and its effects on bone metabolism after a 3-year therapy with pure, standardized genistein (54 mg/day).

design: the parent study was a randomized, double-blind, placebo-controlled trial involving 389 osteopenic, postmenopausal women for 24 months. after the 24-month visit, a sub-population (138 patients) accepted to continue the intervention until 36 months, thus generating a follow-up study. setting: 3 italian university medical centers. interventions: participants received 54 mg of genistein, daily, (n=71) or placebo (n=67). both intervention and placebo contained calcium and vitamin d3. all patients also received dietary instruction in an isocaloric fat-reduced diet. measurements: mammographic breast density at baseline and after 24 and 36 months was assessed by visual classification scale and by digitized quantification. brca1 and brca2 molecular message, sister chromatid exchanges and endometrial thickness were also evaluated at the same time points. measurements of lumbar spine and femoral neck bmd and qus t-score were assayed in our patients. secondary outcomes were serum levels of b-alp, igf-i, srankl, osteoprotegerin and urinary excretion of ctx, pyridinoline and deoxypyridinoline. furthermore insulin resistance (homa-ir), glucose levels, homocysteine and hot flushes were also evaluated. in addition for thyroid safety tsh, ft3, ft4, thyroid autoantibodies, and mrna for thyroid and retinoid receptors were evaluated.

Eligibility criteria:
inclusion criteria: * good general health * have not had a menstrual period in the preceding year * had not undergone surgically induced menopause * had a follicle-stimulating hormone level \> 50 iu/liter and a serum 17 beta-estradiol level ≤ 100 pmol/liter * established osteopenia (-1\<t-score\<-2.5 sd) exclusion criteria: * clinical or laboratory evidence of confounding systemic diseases, such as cardiovascular, hepatic, or renal disorders * coagulopathy, use of oral or transdermal estrogen, progestin, androgen or other steroids * biphosphonates, cholesterol-lowering therapy or cardiovascular medications in the preceding six months * smoking habit of more than two cigarettes per day * previous treatment with any drug that could affect the skeleton in the preceding year * a family history of estrogen-dependent cancer * bmd at femoral neck \> 0.795 g/cm2; this bmd value corresponds to a t score of -1 standard deviation

Keywords: genistein bone mineral density digital mammography safety
improving symptom self-management in adolescents & young adults with cancer

Conditions: Symptom Clusters; Cancer

Summary: this study evaluates the use of the computerized symptom capture tool (c-scat), which creates an image of the symptoms the participant is experiencing, for improving symptom self-management in adolescents and young adults with cancer. in this one-group trial, participants will complete the c-scat and use it during two clinic visits with their oncology providers.

unrelieved symptoms lead to poorer quality of life for adolescents and young adults (ayas) with cancer. strategies are needed to help ayas manage symptoms. the investigators developed the computerized symptom capture tool (c-scat), a novel way to assess symptoms where ayas create a picture of their symptoms using images and text on an ipad app. the resulting image shows symptoms/symptom clusters, priority symptoms and relationships between symptoms and has potential to support aya's symptom self-management. facilitating the self-management process, including self-efficacy, self-regulation behaviors, and patient-provider communication, is essential for improving symptom outcomes.

Eligibility criteria:
inclusion criteria: * 15 to 29 years of age with a diagnosis of cancer (primary, relapsed/recurrent, refractory, progressive, or secondary malignancy) receiving myelosuppressive chemotherapy. * completion of at least one cycle of therapy for cancer and anticipated to have at least two additional cycles of myelosuppressive chemotherapy as part of the treatment plan. * ability to speak and understand english as required to complete the c-scat and study measures. * ability to use a tablet computer. exclusion criteria: * cognitive and/or physical inabilities to complete the proposed study measures as determined by self--report, parent report of minor, or medical chart.

Keywords: adolescents young adults
measurement of eye blood flow and renal function in healthy and diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to the determine the effect of salt intake and captopril on the ophthalmic artery (oa) blood supply of individuals with type 2 diabetes mellitus.

the overall objective of this study is to ascertain if salt intake affects ophthalmic artery (oa) blood flow. in addition, we will study both the eye and kidney response to ace inhibition compared to placebo while controlling salt intake in subjects with type 2 diabetes mellitus. we hypothesize that salt intake will affect oa blood flow. we will initially look at both eye and renal response to subjects on a low salt diet (10meq na/day) followed by response to high salt diet (200meq na/day). in addition, we may look at eye response while subjects consume their regular diet.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus exclusion criteria: * type 1 diabetes mellitus * heart attack or stroke within the last 6 months * pregnant or lactating females
receptive music interventions during intradermal testing in children

Conditions: Music Therapy; Anxiety; Pain Management; Skin Tests; Child

Summary: the study summary and design were to assess procedural anxiety and stress in parents and pain perception in children during intradermal testing. music medicine was incorporated into the study design as a nonpharmacological intervention. two distinct auditory modalities were used: solfeggio frequencies-174 hz, 285 hz, 396 hz, and 528 hz-which have been suggested to interact with the human energy field through resonance-based mechanisms, and turkish classical musical modes (makams), such as rast, hicaz, uşşak, neva, and saba, which are modal systems that include microtonal intervals and follow specific melodic progressions that are often associated with different emotional and spiritual effects as well as sensory and emotional regulation potential.


Eligibility criteria:
inclusion criteria: 1. children aged between 2 and 17 years 2. referred to the pediatric allergy clinic for evaluation of suspected drug hypersensitivity reactions 3. accompanied by a parent or legal guardian willing to participate 4. written informed consent obtained from parents or legal guardians exclusion criteria: 1. known neurological, psychiatric, or developmental disorders in the child 2. use of sedatives or analgesic medications within 24 hours prior to testing 3. hearing impairment or auditory processing disorders in the child4.non-consent or withdrawal of consent by parent or guardian 4. inability of the parent to complete anxiety assessments (e.g., due to language or cognitive barriers)
clinical impact of covid-19 by p.1 sars-cov-2 lineage

Conditions: Covid19; COVID-19 Pneumonia; SARS-CoV-2 Infection

Summary: since the first report of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) variant of concern (voc) p.1 in manaus, brazil, a rapid spread of this lineage across the country has been observed. recent studies indicate that this variant is associated with higher transmissibility; it is not known whether it is associated with clinical severity and higher mortality rates. this is a retrospective cohort study carried out at hospital de clínicas de porto alegre. adult patients aged 18 years or more and 65 years or less who were admitted to the hospital due to symptomatic covid-19 from june 2020 to may 2021 and had a reverse transcriptase-polymerase chain reaction (rt-pcr) cycle threshold value for either sars-cov-2 n1 or n2 target ≤ 25 were eligible to the study. samples from 86 patients (43 from june 2020 to november 2020 and 43 from february 2021 to may 2021) were sequenced for further evaluation. these dates were defined since the emergence of p.1 lineage in late january. clinical data regarding ventilatory support, date of onset of symptoms, laboratory findings and mortality were collected from each patient. this retrospective cohort aims to assess whether the number of days needed for supplementary oxygen either by noninvasive ventilation or high-flow nasal cannula from onset of symptoms differs among patients infected with the p.1 sars-cov-2 variant and those infected with other variants.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 65 years * hospital admission due to symptomatic covid-19 * rt-pcr was collected from june to november 2020 or from february to may 2021 exclusion criteria: * patients admitted for reasons other than covid-19 * asymptomatic patients with positive routine screening with rt-pcr * patients transferred from other institutions
preimplant site augmentation using mpm versus autogenous bone graft

Conditions: Bone Resorption

Summary: using growth factors obtained from patient's venous blood mixed with particulate autogenous bone the study compares bone gain by implant with gold standards.

to study the effectiveness of mpm in ridge augmentation with implant insertion compared with autogenous bone graft. -pico- population (p): patients with defective maxillary alveolar ridge requiring implant insertion. intervention (i): ridge augmentation with mpm. comparator (c): autogenous bone graft. outcome (o): patient satisfaction - implant stability.

Eligibility criteria:
inclusion criteria: 1. medically free patients. 2. evaluated bone height on cbct to be (0-4 mm buccal bone dehiscence) and width (not less than 4.5 mm) 3. patients with anterior maxillary defective partially edentulous ridge. 4. age between 18 and 40 years. 5. both sexes. 6. patients physically able to tolerate surgical and restorative procedures. 7. patients with an opposing tooth to the pre-implant site. 8. good oral hygiene. 9. highly motivated patients. exclusion criteria: 1. patients allergic to local anesthetic agent. 2. pregnant or lactating females. 3. presence of any pathosis in the pre-implant site. 4. presence of any mucosal disease. 5. presence of parafunctional habits. 6. history of oral radiotherapy. 7. history of prolonged steroids use. 8. psychological disorders.
endothelial progenitor cells

Conditions: Coronary Artery Disease

Summary: vascular stenosis as a result of neointimal hyperplasia is a major clinical problem that has an impact on multiple and diverse disciplines, including cardiology (coronary restenosis), cardiothoracic and vascular surgery (saphenous vein and polytetrafluoroethylene \[ptfe\] graft failure), neurology (carotid stenosis), nephrology (dialysis access dysfunction), and transplant medicine (chronic allograft rejection in hearts and kidneys). \[1\] in marked contrast to the deleterious effects of smooth muscle progenitor cells on neointimal hyperplasia, circulating endothelial progenitor cells (epcs) are believed to play an important role in vascular repair and in the inhibition of neointimal hyperplasia. \[2\] endothelial progenitor cells (epcs) circulate in adult peripheral blood and contribute to neovascularization. satoshi et al. have demonstrated that lineage-committed epcs and cd34-positive mononuclear cells, their putative precursors, are mobilized during an acute ischemic event in humans. \[3\] reduced levels of circulating epcs independently predict atherosclerotic disease progression, thus supporting an important role for endogenous vascular repair to modulate the clinical course of coronary artery disease. \[4\] these observations prompt the hypothesis that circulating epcs may provide an endogenous repair mechanism to counteract surgery-induced endothelial cell injury and to replace dysfunctional endothelium perioperatively. therefore, the investigators examined whether levels of circulating epcs correlate with time course and outcomes of coronary artery bypass surgery to establish a clinical role of endogenous endothelial repair mediated by circulating epcs.


Eligibility criteria:
inclusion criteria: * age from 18 to 85 years * signed written informed consent * angiographically documented coronary artery disease and indicated for coronary artery bypass surgery exclusion criteria: * clinical or biochemical evidence for the presence of concomitant inflammatory disease * chronic renal insufficiency (serum creatinine \> 1.4 mmol/l) * impaired left ventricular ejection fraction (\< 45%) * autoimmune or malignant disease * thrombocytopenia (\< 100 000/l) * anemia (hemoglobin \< 8.5 g/dl) * inability to understand the consent form * previous coronary bypass surgery * severe peripheral arterial occlusive disease or atrial fibrillation

Keywords: endothelial progenitor cell coronary artery bypass
treatment of chronic thoracic and neck and upper extremity pain

Conditions: Back Pain; Neck Pain

Summary: to study improvements or lack thereof with the interlaminar epidural patients with or without steroids experiences mid back, upper back or neck pain with or without chest wall and upper extremity pain of at least 6-months duration non-responsive to conservative management.

this is a single-center, prospective, controlled, double-blind, randomized study in thoracic and cervical regions. patients are studied in 2 groups in each region. * group i-local anesthetic only. * group ii-local anesthetic with 6 mg of non-particulate celestone. all patients will be unblinded at 12 or 24 months. non-responsive patients will be unblinded after 3 months and will be crossed over to a different group, if patient consents. non-responsive patients may be unblinded and withdrawn from the study at any time.

Eligibility criteria:
inclusion criteria: * subjects of at least 18 years of age * subjects with a history of chronic, function-limiting thoracic or cervical pain with or without upper extremity pain of at least 6 months in duration * subjects who are able to give voluntary, written informed consent to participate in this investigation * subjects who, in the opinion of the pi, are able to understand this investigation, co-operate with the investigational procedures, and are willing to return to the center for all the required post-operative follow-ups * subjects have not had recent surgical procedures within the last 3 months. exclusion criteria: * compressive radiculopathy * narcotic use of no greater than hydrocodone 100 mg/day, methadone of 60 mg, or morphine 180 mg, or dose equivalent * uncontrolled major depression or uncontrolled psychiatric disorders * uncontrolled or acute medical illnesses including coagulopathy, renal insufficiency, chronic liver dysfunction, progressive neurological deficit, urinary sphincter dysfunction, infection, increased intracranial pressure, pseudotumor cerebri, intracranial tumors, unstable angina, and severe chronic obstructive pulmonary disease * chronic severe conditions that could interfere with the interpretations of the outcome assessments for pain and bodily function * women who are pregnant or lactating * subjects who have participated in a clinical study with an investigational product within 30 days of enrollment * patients with multiple complaints involving concomitant shoulder osteoarthritis, due to the overlap of pain complaints * inability to achieve appropriate positioning and inability to understand informed consent and protocol * history of adverse reaction to local anesthetic or anti-inflammatory drugs and history of gastrointestinal bleeding or ulcers.
circle method observational project - non-interventional, retrospective, multicenter data collection

Conditions: Aortic Stenosis With Bicuspid Valve

Summary: the goal of this non-interventional, retrospective data analysis is to validate the circle method for patients with bicuspid aortic heart valves undergoing transcatheter aortic heart valve implantation (tavi). the main aims are: * to assess whether patients with bicuspid aortic valves that received a tavi suffered from fewer complications * if valve size was identical to the one determined using the circle method compared to * a case where circle method derived valve size is different from the actually implanted valve * to develop recommendations on how to size the valve using the circle method.

the bicuspid aortic valve (bav) is the most common heart valve abnormality and is associated with a number of cardiac complications, including infective endocarditis, aortic dissection, aortic dilatation, and the development of severe aortic stenosis (as). due to its anatomical characteristics bav has been considered a contraindication to transcatheter aortic valve implantation (tavi), a standard treatment of as. however, several recent trials have presented promising results indicating tavi to be a safe alternative to surgery for low risk patients and more patients with bav have been considered for tavi. there are several sizing techniques for tavi in bav, including an annular sizing, a supra-annular sizing, and a balloon sizing, yet there is still no consensus on the most appropriate technique. although annular sizing remains the major approach in most patients with bav, some bav anatomies may profit from the supra-annular sizing. recently published consensus for sizing and positioning the balloon-expandable edwards sapien 3 transcatheter heart valve (thv) in bav describes the anatomical features that influence sizing optimization. the novel circle technique has also been proposed in the presence of the unique anatomical factors and sizing at the supra-annular level. this method is particularly helpful for visually identifying anatomic features, indicating the sealing zone at the commissures, visually reassuring of the size and position, and treating patients with large annuli. currently, there are limited data validating the circle method for identifying sizing and positioning for tavi in bav patients. in this non-interventional, retrospective, multicenter data collection and analysis we aim to validate the circle method for sizing and positioning in bicuspid aortic valves. due to the non-interventional character of the project, no additional burden will be put on the patients eligible for inclusion.

Eligibility criteria:
inclusion criteria: * patients with bicuspid aortic valves who underwent aortic valve replacement with a balloon expandable valve (sapien 3 / ultra) * computed tomography data available exclusion criteria: - none